A unique collection of 960 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS); All compounds have been permitted into clinical trial phases, categorized into Phase 1, Phase 2 and Phase 3. An effective tool for new drug screening and cell differentiation induction; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality;
